Succeeding in the 2020 US Cell Surface Testing Market: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

Succeeding in the 2020 US Cell Surface Testing Market: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

  • February 2020 •
  • 115 pages •
  • Report ID: 5861932 •
  • Format: PDF
Succeeding in the 2020 US Cell Surface Testing Market: Supplier Shares and Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers

The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies. During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.

This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, including clinical significance and current laboratory practice, as well as five-year test volume forecasts by market segment.

Companies Profiled
Competitive Assessments

- Abbott
- Agilent Technologies
- Beckman Coulter/Danaher
- Becton Dickinson
- Bio-Rad
- CellaVision
- Horiba
- Nihon Kohden
- Ortho-Clinical Diagnostics
- Roche
- Siemens Healthineers
- Sysmex